Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Park, Min-Hyeon | - |
dc.contributor.author | Marks, David M. | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.date.accessioned | 2021-09-08T21:05:49Z | - |
dc.date.available | 2021-09-08T21:05:49Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2009-01 | - |
dc.identifier.issn | 1472-4472 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/120824 | - |
dc.description.abstract | Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Wyeth, is a novel salt form of the isolated major active metabolite of the antidepressant venlafaxine. Desvenlafaxine was developed as a slow-release tablet formulation and rapidly penetrates the brain upon administration supporting its direct effects on neuronal systems of the brain. Unlike various other antidepressants including venlafaxine, desvenlafaxine is not metabolized by cytochrome p450 (CYP) enzyme pathways and is associated with minimal inhibition of CYP enzymes. This feature results in a comparatively low risk of drug-drug interaction and consistent intra-individual and inter-individual pharmacokinetic profiles. Desvenlafaxine has been recently approved by the US FDA for the treatment of major depressive disorder (MDD) based on a series of randomized, double-blind, placebo-controlled clinical trials indicating efficacy and safety for patients with MDD. Studies have also supported the potential utility of desvenlafaxine in the treatment of vasomotor symptoms of menopause, anxiety symptoms and painful physical symptoms. However, concerns including mixed efficacy and adverse events need to be further explored in future studies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | THOMSON REUTERS (SCIENTIFIC) LTD | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | STAR-ASTERISK-D | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | REUPTAKE INHIBITOR | - |
dc.subject | POOLED ANALYSIS | - |
dc.subject | THERMOREGULATORY DYSFUNCTION | - |
dc.subject | ADULT OUTPATIENTS | - |
dc.subject | HEALTHY-SUBJECTS | - |
dc.subject | SUCCINATE | - |
dc.subject | EFFICACY | - |
dc.title | Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.scopusid | 2-s2.0-58449120178 | - |
dc.identifier.wosid | 000262464500008 | - |
dc.identifier.bibliographicCitation | CURRENT OPINION IN INVESTIGATIONAL DRUGS, v.10, no.1, pp.75 - 90 | - |
dc.relation.isPartOf | CURRENT OPINION IN INVESTIGATIONAL DRUGS | - |
dc.citation.title | CURRENT OPINION IN INVESTIGATIONAL DRUGS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 75 | - |
dc.citation.endPage | 90 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | STAR-ASTERISK-D | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | REUPTAKE INHIBITOR | - |
dc.subject.keywordPlus | POOLED ANALYSIS | - |
dc.subject.keywordPlus | THERMOREGULATORY DYSFUNCTION | - |
dc.subject.keywordPlus | ADULT OUTPATIENTS | - |
dc.subject.keywordPlus | HEALTHY-SUBJECTS | - |
dc.subject.keywordPlus | SUCCINATE | - |
dc.subject.keywordPlus | EFFICACY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.